Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed director
QSAM Biosciences, Inc. (QSAM) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES PURCHASE AGREEMENT QSAM BIOSCIENCES - COMMON STOCK This Securities Purchase Agreement , between QSAM Biosciences Inc., a Delaware corporation, and the purchaser set forth below , is dated as of the date signed by the Company . The Company and the Purchasers may be referred to individually, as a “Party” and collectively, as the “Parties.” WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act of 1933, as amended , and Rule 506 promulgated thereunder, the Company desires to issue and sell to the Purchasers, and the Purchasers, desires to purchase from the Company, securities of the Company as more fully described in this Agreement . NOW THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,..."
08/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data"
05/12/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
04/04/2023 8-K Unregistered Sales of Equity Securities  Interactive Data
03/22/2023 8-K Investor presentation
01/25/2023 8-K Investor presentation
01/10/2023 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
03/09/2022 8-K Quarterly results
03/04/2022 8-K Quarterly results
01/28/2022 8-K Appointed a new director
Docs: "Independent Director Compensation",
"QSAM Biosciences Appoints Adriann Sax to Board of Directors Austin, TX; January 25, 2022 – QSAM Biosciences Inc . , a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP , for the treatment of cancer and related diseases, today announces the appointment of Adriann Sax to the QSAM Biosciences Board of Directors. Ms. Sax will serve on the Company’ s Audit Committee and will chair the Nomination and Governance Committee. Ms. Sax has a distinguished 30+ year career in biotech and life sciences, serving in leadership, operational and business development roles with a focus on oncology for both Fortune 100 and start-up companies. She currently serves as CEO and co-founder of Vetigenics LLC, an animal health biotech company, where she has secured part..."
12/10/2021 8-K Quarterly results
12/08/2021 8-K Quarterly results
11/30/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "FIRST AMENDMENT Patent and Technology License Agreement and Trademark Assignment Between IGL Pharma, Inc. and QSAM Therapeutics Inc. This Patent and Technology License Agreement and Trademark Assignment Amendment is made and entered into as of November 17, 2021 , by and between IGL Pharma, Inc., a Delaware corporation, having its principal place of business at 1004 S. Velasco Street, Angleton, Texas 77515 and QSAM Therapeutics Inc., a Texas corporation having its principal place of business 3616 Far West Blvd, Suite 117-292, Austin, Texas 78731. IGL Pharma and QSAM are each referred to herein as a “ Party ” and collectively as the “ Parties . ” The Parties desire to amend their Patent and Technology License Agreement and Trademark Assignment, effective April 20, 2020 by this Amendment, whi..."
10/21/2021 8-K Unregistered Sales of Equity Securities  Interactive Data
04/20/2021 8-K Quarterly results
02/18/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/28/2021 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
Docs: "Form of Securities Purchase Agreement for Series B Convertible Preferred Stock",
"Form of Warrant for the Purchase of Shares of Common Stock",
"QSAM Biosciences Closes Series B Preferred Private Placement; $2.5 Million in New Capital to Fund Upcoming Clinical Trials"
12/31/2020 8-K Quarterly results
11/10/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Cost Associated with Exit or Disp...
Docs: "Omnibus Separation Agreement, between the Company and Earth Property Holdings, LLC",
"Employment Agreement dated November 6, 2020, between the Company and Douglas Baum",
"Employment Agreement dated November 6, 2020, between the Company and C. Richard Piazza",
"QSAM Biosciences Advances Plan of Separation from Legacy Business",
"Pro-forma financial statements for the periods ended December 31, 2019 and June 30, 2020"
09/11/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Amendment of the Amended and Restated Articles of Incorporation of Q2Earth, Inc",
"Q2Earth Changes Name to QSAM Biosciences, Inc.; Will Commence Trading Under Symbol QSAM in 20 Business Days Palm Beach, FL; September 10, 2020 – Q2Earth Inc. announced today that it has filed an amendment to its Certificate of Incorporation and has received FINRA approval to change the company’ s name to QSAM Biosciences, Inc., and will commence trading under the new stock symbol QSAM within 20 business days. The company has also enacted a 25:1 reverse stock split effective today and increased its authorized common stock to 300 million shares, as approved by its stockholders in January 2020. The name change to QSAM Biosciences is meant to reflect the new direction of the company, after securing the exclusive, worldwide rights to a clinical stage novel radiopharmaceutical called CycloSam® w..."
04/24/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Patent and Technology License Agreement and Trademark Assignment between IGL Pharma, Inc. and QSAM Therapeutics Inc.",
"Consulting and Confidentiality Agreement by and between IGL Pharma, Inc. and QSAM Therapeutics Inc."
02/07/2020 8-K Submission of Matters to a Vote of Security Holders
01/17/2020 8-K Appointed a new director
Docs: "Q2Earth Appoints Douglas Baum, Senior Biosciences Executive, To Board of Directors Palm Beach, FL; January 16, 2020 – Q2Earth, Inc . announced today that it has appointed Douglas R. Baum to its Board of Directors. Mr. Baum brings to the Company over 28 years of experience in the bioscience and biotech industries, including development, commercialization and marketing of multiple drugs and medical devices. Over his long senior executive tenure, including as CEO of Xeris Pharmaceuticals, he has overseen 15 product approvals through the FDA and raised over $80 million in capital to fund breakthrough technologies. “We are pleased and honored to have Doug join our board. We have a great deal of faith that he can help us pursue a strategy that includes expanding our licensing portfolio and busi..."
05/22/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Transaction Services Agreement between Q2Earth, Inc. and Community Eco Power LLC",
"Q2Earth Signs Services Agreement in Connection with Acquisition of Two Waste-to-Energy Plants in New England Palm Beach, FL; May 21, 2019 - Q2Earth, Inc . has signed a services agreement to oversee the operational, legal and financial closing of the acquisition of two waste-to-energy plants in New England on behalf of its client, Community Eco Power LLC , and to assist in post-closing integration matters. The closing between the seller and CEP occurred on May 15, 2019. For its services to CEP prior to closing and over the following six months, the Company will receive a fee of $250,000. Q2 also received rights to build compost facilities on or around the sites over the next two years subject to permitting and other qualifications, and to invest in future CEP funding rounds. The facilities..."
04/02/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Q2Earth Provides Update Letter to Shareholders on 2018 Operational Results and Value Creation Strategy Palm Beach, FL; April 2, 2019 - Q2Earth, Inc . provided the following letter to shareholders today: Dear Q2Earth Shareholders: We are pleased to provide this summary of progress made by Q2Earth during 2018 and the first quarter of 2019. The information provided in this update letter is qualified by the detailed disclosures, including financial statements and risk factors, provided in our Form 10-K for the year ended December 31, 2018, as filed with the Securities Exchange Commission on April 1, 2019. Q2Earth is in the business of overseeing the acquisition and management of companies that manufacture and support compost and soil products from waste streams. Soil health is a critical envir..."
01/23/2019 8-K Entry into a Material Definitive Agreement, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, ...
Docs: "Subscription Agreement for Class B Units in Earth Property Holdings LLC",
"Form of Amended and Restated Limited Liability Company Agreement of Earth Property Holdings LLC",
"Letter of EisnerAmper LLP to the SEC",
"Q2Earth, through Affiliated Entity, Completes Acquisition of Leading Organics Composting Company in Austin, Texas Palm Beach, FL; January 23, 2019 - Q2Earth, Inc . through an affiliated entity called Earth Property Holdings LLC has completed the acquisition of all of the partnership interests of Organics “By Gosh” in Austin, Texas . Phil and Donna Gosh and their committed team, the “heart and soul” of OBG and the organics composting community in Austin, will continue to run the business providing the highest quality products and service to their customers and vendors, while also joining the Q2/Earth Property family to execute strategic growth. OBG will continue to be operated as before the transaction, with the same location, staff, name and company structure. The mission of Organics “By ..."
11/13/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Transfer and Assignment Agreement between Q2Earth, Inc. and Earth Property Holdings, LLC",
"Management Agreement between Q2Earth, Inc. and Earth Property Holdings, Inc",
"Limited Liability Company Agreement of Earth Property Holdings, Inc.",
"Q2Earth, through Affiliated Entity, Completes Acquisition of Leading Company In Residual Waste Management, Composting for Paper Industry Palm Beach, FL; November 13, 2018 - Q2Earth, Inc . through an affiliated entity called Earth Property Holdings LLC has completed the acquisition of George B. Wittmer Associates Inc . . GBWA is a leading residual waste management and compost manufacturing company that services multiple papermills in the southeast United States. The company’ s headquarters and main composting site is located outside of Jacksonville, Florida. Assets acquired in the stock transaction include equipment, inventory, proprietary know-how, land , and contracts with some of the largest paper product manufacturers in the U.S. “We are very excited to carry on the long history of exc..."
08/06/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy